Evidence map›Paper›PMID 41737139›Full record

ArticleCancer management and research2026

Clinicopathological and Genomic Analysis of

Dongmei Chen, Heng Zhang, Diming Wang, Wei Ye, Hongfei Zhao, Chi Zhang, Sihan Wu, Qingming Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dongmei Chen *Department of Oncology, Anhui Chest Hospital, Hefei, Anhui, 230022, People's Republic of China.ORCID 0009-0003-0362-0838
Heng Zhang *Department of Oncology, Anhui Chest Hospital, Hefei, Anhui, 230022, People's Republic of China.
Diming WangDepartment of Oncology, Anhui Chest Hospital, Hefei, Anhui, 230022, People's Republic of China.ORCID 0000-0002-1629-6171
Wei YeDepartment of Oncology, Anhui Chest Hospital, Hefei, Anhui, 230022, People's Republic of China.ORCID 0000-0002-2184-8911
Hongfei ZhaoDepartment of Oncology, Anhui Chest Hospital, Hefei, Anhui, 230022, People's Republic of China.
Chi ZhangDepartment of Oncology, Anhui Chest Hospital, Hefei, Anhui, 230022, People's Republic of China.
Sihan WuDepartment of Oncology, Anhui Chest Hospital, Hefei, Anhui, 230022, People's Republic of China.
Qingming ShiDepartment of Oncology, Anhui Chest Hospital, Hefei, Anhui, 230022, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: This retrospective cohort study included 47 patients with pathologically confirmed Results: The cohort was predominantly older male smokers (median age 66; 87% male) with advanced disease (47% with distant metastasis at diagnosis). Imaging typically showed large, necrotic masses with ill-defined borders. Adenocarcinoma was the most common subtype (60%). Immunohistochemistry revealed BRG1 loss (91%), frequent Conclusion:

Indexed as

BRG1 lossimmunohistochemistrymolecular profilingprognosisSMARCA4-deficient lung cancertreatment outcome

Identifiers

PMID41737139
PMCPMC12927861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.